NCT01672736 - A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 27, 2017

Study Completion Date

December 27, 2017

Conditions

Multiple Myeloma

Interventions

DRUG

ASP7487, Velcade, Dexamethasone

ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration

Trial Locations (6)

30322

Emory University Winship Cancer Institute, Atlanta

60637

University Of Chicago Medical Center, Chicago

B3H2Y9

Queen Elizabeth II Health Sciences Center, Halifax

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

H3T 1E3

Sir Mortimer B. Davis-Jewish General Hospital, Montreal